Breaking News

Ligand Earns Milestone for NOXAFIL Approval

By Kristin Brooks | March 17, 2014

Will sell Captisol-enabled formulation to Merck

Ligand Pharmaceuticals Inc.has earned a $1 million milestone payment from Merck following the FDA approval of NOXAFIL (posaconazole) injection (18 mg/mL), a new Captisol-enabled formulation for intravenous use. Under a commercial supply agreement, Ligand will sell Captisol to Merck for this product.
“We congratulate the project team at Merck on this important advancement in the treatment of invasive fungal infections,” said John Higgins, president and chief executive officer of Ligand Pharmaceuticals. “Ligand's business is thriving with the continued success of our partners with late-stage clinical and regulatory events. This is the second new product expected to be made available in 2014 following the launch of Duavee last month by Pfizer and three additional Ligand-partnered programs are pending approvals in 2014. Captisol is a proven formulation that is garnering more interest by prospective customers and partners given the technology’s elevated profile.”
NOXAFIL injection for intravenous use is indicated for prophylaxis of invasive Aspergillus and Candida infections in patients who severely immunocompromised.
  • U.S. Pharma Market Trends

    Kristin Brooks, Contract Pharma||April 8, 2016
    CPhI Report sees return of generic and API manufacturing to U.S. market

  • DCAT Week ’16 Session Highlights

    Kristin Brooks, Contract Pharma||March 24, 2016
    API and Dose CMO Market Trends and Supply Strategies

  • Talking Trends with Aesica

    Talking Trends with Aesica

    Tim Wright, editor||February 26, 2016
    Managing director Ian Muir fills us in on the latest at the CDMO